FWM
GRCE

Frontier Wealth Management’s Grace Therapeutics GRCE Stock Holding History

Frontier Wealth Management’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-208
Closed -$3K – 405
2020
Q4 		$3K Buy
+208
New +$2.4K ﹤0.01% 374
2020
Q3 		– Sell
-351
Closed -$8K – 375
2020
Q2 		$8K Hold
351
– – ﹤0.01% 345
2020
Q1 		$6K Buy
+351
New +$12.4K ﹤0.01% 285

Other funds holding GRCE

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return

Frontier Wealth Management's GRCE Position: Q1 2021 in Review

Frontier Wealth Management sold out of Grace Therapeutics (GRCE) in Q1 2021, closing a stake of 208 shares — an estimated $3K sold.

Frontier Wealth Management first reported a position in GRCE in Q1 2020 and held it in 3 quarters. The position peaked at $8K in Q2 2020. 24 funds tracked by Wall St. Rank hold GRCE as of Q1 2021.

  • Frontier Wealth Management reported no remaining Grace Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Frontier Wealth Management sold 208 Grace Therapeutics shares in Q1 2021, an estimated $3K.
  • Frontier Wealth Management first reported a position in Grace Therapeutics in Q1 2020 and held it in 3 quarters.
  • Frontier Wealth Management's Grace Therapeutics position peaked at $8K in Q2 2020.
  • 24 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2021.

Based on Frontier Wealth Management's 13F filing for Q1 2021, filed 17 May 2021.